» Articles » PMID: 35437584

The Role of Socioeconomic Status and Race/Ethnicity in Malignant Peripheral Nerve Sheath Tumor Survival: A Surveillance, Epidemiology, and End Results-Based Analysis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent investigations of malignant peripheral nerve sheath tumor (MPNST) survival have reported higher mortality among non-White individuals. However, previous analyses have not examined the impact of socioeconomic status (SES) on these observations. This study aims to characterize factors associated with cause-specific MPNST survival, including information related to census-tract-level SES (CT-SES).

Methods: We identified 2,432 primary MPNSTs using the Surveillance, Epidemiology, and End Results (SEER) 18 (2000-2016) database. We used Cox proportional hazards modeling to estimate the effects of sex, race/ethnicity, CT-SES quintile, metastasis at diagnosis, tumor site, age at diagnosis, and treatment by surgery on survival. Models were fit in both the full population and, separately, stratified by race/ethnicity and age at diagnosis (<40 vs. ≥40).

Results: In adjusted models, age at diagnosis, CT-SES, and metastasis at diagnosis were associated with mortality. In race/ethnicity-stratified analysis, higher CT-SES was found to improve survival only in the White population. Among those diagnosed before age 40, metastasis at diagnosis and American Indian/Alaska Native race/ethnicity were associated with mortality, and both Hispanic ethnicity and Asian/Pacific Islander race were suggestive for increased mortality. Among cases, diagnoses at age 40 and above, age at diagnosis, male sex, and CT-SES were associated with mortality.

Conclusions: This analysis provides evidence that among pediatric and young adult patients, non-White populations experience inferior survival compared with Whites, independent of CT-SES. Our findings also suggest that the effect of CT-SES on MPNST survival may differ by racial/ethnic group.

Impact: These findings suggest that barriers to healthcare for certain racial/ethnic groups extend beyond SES.

Citing Articles

Malignant Peripheral Nerve Sheath Tumors: Latest Concepts in Disease Pathogenesis and Clinical Management.

Yao C, Zhou H, Dong Y, Alhaskawi A, Hasan Abdullah Ezzi S, Wang Z Cancers (Basel). 2023; 15(4).

PMID: 36831419 PMC: 9954030. DOI: 10.3390/cancers15041077.

References
1.
Uusitalo E, Rantanen M, Kallionpaa R, Poyhonen M, Leppavirta J, Yla-Outinen H . Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol. 2016; 34(17):1978-86. DOI: 10.1200/JCO.2015.65.3576. View

2.
Mowery A, Clayburgh D . Malignant peripheral nerve sheath tumors: Analysis of the national cancer database. Oral Oncol. 2019; 98:13-19. DOI: 10.1016/j.oraloncology.2019.09.010. View

3.
Martino S, Elliott M, Hambarsoomian K, Garcia A, Wilson-Frederick S, Gaillot S . Disparities in Care Experienced by American Indian and Alaska Native Medicare Beneficiaries. Med Care. 2020; 58(11):981-987. DOI: 10.1097/MLR.0000000000001392. View

4.
Biotteau M, Dejean S, Lelong S, Iannuzzi S, Faure-Marie N, Castelnau P . Sporadic and Familial Variants in NF1: An Explanation of the Wide Variability in Neurocognitive Phenotype?. Front Neurol. 2020; 11:368. PMC: 7214842. DOI: 10.3389/fneur.2020.00368. View

5.
Martin E, Coert J, Flucke U, Slooff W, Ho V, van der Graaf W . A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer. 2019; 124:77-87. DOI: 10.1016/j.ejca.2019.10.014. View